Endometriosis Pipeline Insight

DelveInsight’s, “Endometriosis – Pipeline Insights, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Endometriosis Understanding

Endometriosis: Overview

Endometriosis is a disease in which the endometrium (the tissue that lines the inside of the uterus or womb) is present outside of the uterus. Endometriosis most commonly occurs in the lower abdomen or pelvis, but it can appear anywhere in the body. Symptoms of endometriosis include lower abdominal pain, pain with menstrual periods, pain with sexual intercourse, and difficulty getting pregnant. On the other hand, some women with endometriosis may not have any symptoms at all.

Symptoms

The following are the most common symptoms for endometriosis, but each woman may experience symptoms differently or some may not exhibit any symptoms at all. Symptoms of endometriosis may include:

• Pain, especially excessive menstrual cramps that may be felt in the abdomen or lower back
• Pain during intercourse
• Abnormal or heavy menstrual flow
• Infertility
• Painful urination during menstrual periods
• Painful bowel movements during menstrual periods
• Other gastrointestinal problems, such as diarrhea, constipation and/or nausea

Diagnosis

Some physicians may treat suspected endometriosis based on a woman’s symptoms or physical examination findings to see if they improve without proceeding to surgery. However, to formally diagnose endometriosis, a doctor must perform laparoscopy (surgery in which a doctor looks in the abdomen with a camera through the belly button) to visualize and biopsy suspected endometriosis lesions. Endometriosis lesions can vary in appearance.

Treatment

The most conservative therapy for endometriosis is with medications. Non-steroidal anti-inflammatory medications, like ibuprofen, may help with the pain associated with endometriosis. Medications that control a woman’s hormones may also help with endometriosis pain. Some examples are oral contraceptive pills and gonadotropin releasing hormone (GnRH) agonists, the latter of which put women into a “temporary” menopause-like state.

Surgery can diagnose endometriosis, and it can also treat endometriosis via removal (excision) or burning (fulguration) of endometriosis lesions. 

Endometriosis Emerging Drugs Chapters

This segment of the Endometriosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometriosis Emerging Drugs

• Linzagolix: ObsEva /Kissei Pharmaceutical

Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. It is currently in phase III stage of development.

• NS-580: Nippon Shinyaku

NS-580 is being developed by Nippon Shinyaku for the treatment of Endometriosis. It is currently in phase II stage of development.

• LY01007: Luye Pharma

LY01007 is being developed by Luye Pharma for the treatment of Endometriosis. It is currently in phase I stage of development.

Further product details are provided in the report……..

Endometriosis: Therapeutic Assessment

This segment of the report provides insights about the different Endometriosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Endometriosis

There are approx. 100+ key companies which are developing the therapies for Endometriosis. The companies which have their Endometriosis drug candidates in the most advanced stage, i.e. phase III include ObsEva /Kissei Pharmaceutical and others

• Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Endometriosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Endometriosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endometriosis drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Endometriosis R&D. The therapies under development are focused on novel approaches to treat/improve Endometriosis.
• In 2015, ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co., which had completed several phase IIa clinical trials in Japan.

Endometriosis Report Insights

• Endometriosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Endometriosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Endometriosis drugs?
• How many Endometriosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometriosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Endometriosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Endometriosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ObsEva
• Kissei Pharmaceutical
• Nippon Shinyaku
• Luye Pharma
• AbbVie
• Myovant Sciences GmbH
• Nobelpharma
• Dexa Medica Group

Key Products

• Linzagolix
• NS-580
• LY01007
• Elagolix
• Relugolix
• NPC-01
• DLBS1442